CLSI Education Workshop Presentations

Epidemiological Cutoff Values (ECVs): Their Development and Use

Presented on Saturday, January 27, 2018 at the Westin Galleria, Dallas, Texas, USA

• The mathematical and scientific basis for developing and setting epidemiological cut-offs (ECOFFs) by John D. Turnidge, MD, BS, FRACP, FRCPA, FASM, Clinical Advisor, Australian Commission on Safety and Quality in Health Care, Sydney, NSW, Australia
• EUCAST’s perspective on the development and use of ECOFFs by Gunnar Kahlmeter, Professor of Clinical Bacteriology, Head of the EUCAST, Development Laboratory, EUCAST Technical Data Coordinator, Växjö, Sweden
• FDA’s perspective on the development and use of ECVs by Simone M. Shurland, PhD, Microbiology Reviewer, Clinical Microbiology Team HFD-520, CDER/OND/OAP/DAIP, Silver Spring, MD, USA
• Antifungal Susceptibility Testing Committee’s perspective on the development and use of ECVs by Shawn R. Lockhart, PhD, D(ABMM), Director, Fungal Reference Laboratory, Team Lead, Antifungal Laboratory, Mycotic Diseases Branch, Centers for Disease Control and Prevention, Atlanta, GA, USA
• AST SC’s perspective on the development and use of ECVs by Matthew A. Wikler, MD, MBA, FIDSA, President, IDTD Consulting, Rancho Santa Fe, CA, USA